Last reviewed · How we verify
Fluvoxamine+Methylphenidate hydrochloride
This combination uses fluvoxamine to increase serotonin levels in the brain while methylphenidate increases dopamine and norepinephrine, together addressing both mood and attention symptoms.
This combination uses fluvoxamine to increase serotonin levels in the brain while methylphenidate increases dopamine and norepinephrine, together addressing both mood and attention symptoms. Used for Depression with comorbid attention-deficit/hyperactivity disorder (ADHD), Obsessive-compulsive disorder with attentional symptoms.
At a glance
| Generic name | Fluvoxamine+Methylphenidate hydrochloride |
|---|---|
| Sponsor | Guangdong Provincial People's Hospital |
| Drug class | SSRI + stimulant combination |
| Target | Serotonin transporter (SERT) and dopamine/norepinephrine transporters (DAT/NET) |
| Modality | Small molecule |
| Therapeutic area | Psychiatry/Neurology |
| Phase | FDA-approved |
Mechanism of action
Fluvoxamine is a selective serotonin reuptake inhibitor (SSRI) that blocks serotonin reuptake at the presynaptic neuron, increasing serotonin availability in synaptic spaces. Methylphenidate is a stimulant that blocks dopamine and norepinephrine reuptake, enhancing attention and executive function. The combination targets complementary neurotransmitter systems to treat conditions with both depressive/anxiety and attentional components.
Approved indications
- Depression with comorbid attention-deficit/hyperactivity disorder (ADHD)
- Obsessive-compulsive disorder with attentional symptoms
Common side effects
- Insomnia
- Nausea
- Headache
- Anxiety
- Tachycardia
- Decreased appetite
Key clinical trials
- Pharmacokinetics and Safety of Commonly Used Drugs in Lactating Women and Breastfed Infants
- Methylphenidate Hydrochloride Controlled-Release Tablets Augmentation Strategy for Patients With Obsessive Compulsive Disorder (PHASE4)
- Treatment of Youth With ADHD and Anxiety (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: